The Honorable Sylvia Mathews Burwell  
Secretary  
U.S. Department of Health and Human Services  
200 Independence Avenue SW  
Washington, DC 20201  

September 22, 2014  

Dear Secretary Burwell:

Heroin and prescription opioid overdose is reaching record levels in many parts of our country, devastating the lives of individuals, families, and communities. Unlike other diseases, such as cancer or Alzheimer’s, those suffering from addiction often have greater barriers to access to all available treatments. The Department of Health and Human Services (HHS) can and must play a central role in improving the treatment of opioid addiction by improving access to all medicines approved by the Food and Drug Administration (FDA).

To help reverse the increasing incidence of opioid addiction, misuse, overdose, and death – and the many other social ills associated with the spread of opioid addiction – HHS, working with the Substance Abuse and Mental Health Services Administration (SAMHSA), must examine and evaluate its existing strategies for addressing the opioid crisis in our country. HHS should direct SAMHSA to use its existing authority to review current regulations, remove outdated regulatory constraints, and update regulations to incorporate and promote new FDA-approved treatments as they become available.

Right now, the medication a patient is prescribed depends almost entirely upon whether they seek treatment in an Opioid Treatment Program (OTP) or an Office-Based Opioid Treatment Program (OBOT), rather than on the specific clinical needs of that individual patient. Patients who seek treatment at an OTP – also known as a methadone clinic – will almost always be placed on methadone, while patients who seek treatment at an OBOT will almost always be placed on buprenorphine. This treatment limitation exists because these were the only two FDA-approved medications for the treatment of opioid dependence at the time the current regulations were created.

Consequently, regulations have fallen behind as newer FDA-approved medications for treating opioid dependence have become widely available. One extremely important component of a comprehensive response to this crisis requires updating the current regulations governing the treatment of opioid addiction in OTPs and OBOTs so that these settings offer all currently available treatments consistent with the modern practice of medicine. These regulations should be updated to keep pace with medical advances and ensure that patients, working with their health care professionals, are prescribed the most appropriate medication based upon their individual needs rather than the treatment setting they happen to enter. It is important for patients and their physicians to have even-handed access to all available treatments to ensure that patients’ unique needs can be addressed.

Unfortunately, while the number of patients treated in OTPs and OBOTs has increased significantly in the past ten years, the problem of opioid addiction has grown in parallel. It is well recognized that relapse is a contributing factor to the current overdose epidemic, and evidence shows that after patients terminate treatment in OTPs and OBOTs, the rate of relapse to the illicit use of opioids is extraordinarily high. If we are to attempt to reverse incidence of opioid dependence and the increasing numbers of opioid overdoses and opioid-related deaths associated with opioid addiction, it is important that patients have access to all FDA
approved treatment options. As an initial step, SAMHSA should issue changes to existing regulations and guidance governing OTPs and OBOTs, such that:

1) OTP and OBOT practices are required to develop individualized treatment plans for all patients that ensure access to, and treatment with, the most appropriate FDA-approved medication based upon an assessment of that individual patient’s clinical needs;
2) Training requirements for OBOT practitioners are updated to enable physicians in these practices to prescribe and administer all FDA-approved opioid treatment medications, thereby allowing the most appropriate treatment for each patient in their care; and
3) All OTP or OBOT practices are required to develop a relapse prevention plan for each patient completing treatment and be capable of administering continued counseling and medication with a focus on the long-term prevention of relapse to opioid dependence.

It is time to move beyond recognition of the problem and actually treat opioid addiction as a disease and the national priority it is. We have a higher number of effective treatment interventions available today than ever before, and the trend leading to so many tragic consequences can, and must, be reversed. HHS, working with SAMHSA, must modernize its regulations to ensure access to all FDA-approved opioid treatment medications, based on the clinical needs of the patient, and train practitioners to treat this devastating disease in a manner consistent with the treatment of other serious life-threatening illnesses or chronic conditions.

We respectfully request your written response to this letter no later than Friday, November 14, 2014. Additionally, upon receipt of your formal response, we look forward to scheduling a staff briefing to discuss a pathway forward on this important issue.

Sincerely,

RENEE ELLMERS
Member of Congress

STEVE WOMACK
Member of Congress

DORIS MATSUI
Member of Congress

BILL OWENS
Member of Congress

RALPH HALL
Member of Congress

JACK KINGSTON
Member of Congress

SAM FARR
Member of Congress

TOM LATHAM
Member of Congress
ED WHITFIELD
Member of Congress

ROBERT ADERHOLT
Member of Congress

JOHN SHIMKUS
Member of Congress

MIKE SIMPSON
Member of Congress

LEE TERRY
Member of Congress

ANDER CRENSHAW
Member of Congress

JOHN CARTER
Member of Congress

TOM COLE
Member of Congress

MARIO DIAZ-BALART
Member of Congress

JIM GELACI
Member of Congress

PHIL GINGREY
Member of Congress

TIM MURPHY
Member of Congress

TIM RYAN
Member of Congress

GUS BILIRAKIS
Member of Congress

ROBERT E. LATTA
Member of Congress

BILL CASSIDY
Member of Congress
BRETT GUTHRIE  
Member of Congress

PETE OLSON  
Member of Congress

LEONARD LANCE  
Member of Congress

CHELLIE PINGREE  
Member of Congress

TOM ROONEY  
Member of Congress

AARON SCHOCK  
Member of Congress

PAUL TONKO  
Member of Congress

BILL FOSTER  
Member of Congress

LOU BARLETTA  
Member of Congress

RICK CRAWFORD  
Member of Congress

TIM GRIFFIN  
Member of Congress

ANDY HARRIS  
Member of Congress

BILL JOHNSON  
Member of Congress

BILLY LONG  
Member of Congress

ALAN NUNNELEE  
Member of Congress

STEVE STIVERs  
Member of Congress
BILL FLORES  
Member of Congress

MARK AMODEI  
Member of Congress

DAVE JOYCE  
Member of Congress

CHRIS STEWART  
Member of Congress

KEVIN YODER  
Member of Congress

TOM COTTON  
Member of Congress

DOUG LAMALFA  
Member of Congress

DAVID VALADAÑO  
Member of Congress

CC:
Pamela S. Hyde, JD
Administrator
Substance Abuse and Mental Health Services Administration
One Choke Cherry, Room 8-1061
Rockville, MD 20857